Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(11%)
Results Posted
33%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_3
1
11%
Ph phase_1
1
11%
Ph phase_4
3
33%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)
Other(3)

Detailed Status

Completed3
unknown3
Active, not recruiting1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

active_not_recruiting111%
completed333%
not_yet_recruiting111%
terminated111%
unknown333%

Recent Activity

1 active trials
Showing 5 of 9
not_yet_recruitingphase_1

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

NCT07532304
active_not_recruitingphase_2

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
terminatedphase_2

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

NCT06613685
completedphase_4

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

NCT03502005
completedphase_4

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

NCT03998176
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07532304Phase 1

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

Not Yet Recruiting
NCT06544733Phase 2

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

Active Not Recruiting
NCT06613685Phase 2

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Terminated
NCT03502005Phase 4

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Completed
NCT03998176Phase 4

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

Completed
NCT05526118

Advanced HIV: Outcomes for Rapid ART

Unknown
NCT03789968

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

Completed
NCT04155554Phase 3

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen

Unknown
NCT04132674Phase 4

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9